Home
/
Protagenic Therapeutics, Inc.\new
/
Financials
/
Quarterly
Protagenic Therapeutics, Inc.\new — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Protagenic Therapeutics, Inc.\new filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
$0
Mar 9, 2026
Q2
2026
Sep 30, 2025
$0
Nov 26, 2025
Q1
2025
Mar 31, 2025
$0
May 13, 2025
Q3
2024
Sep 30, 2024
$0
Nov 14, 2024
Q2
2024
Jun 30, 2024
$0
Aug 14, 2024
Q1
2025
Mar 31, 2024
$0
May 13, 2025
Q3
2024
Sep 30, 2023
$0
Nov 14, 2024
Q2
2024
Jun 30, 2023
$0
Aug 14, 2024
Q1
2024
Mar 31, 2023
$0
May 15, 2024
Q3
2023
Sep 30, 2022
$0
Nov 14, 2023
Q2
2023
Jun 30, 2022
$0
Aug 14, 2023
Q1
2023
Mar 31, 2022
$0
May 15, 2023
Q3
2022
Sep 30, 2021
$0
Nov 14, 2022
Q2
2022
Jun 30, 2021
$0
Aug 11, 2022
Q1
2022
Mar 31, 2021
$0
May 13, 2022
Q3
2021
Sep 30, 2020
$0
Nov 15, 2021
Q2
2021
Jun 30, 2020
$0
Aug 16, 2021
Q3
2017
Sep 30, 2017
$0
Nov 13, 2017
Q2
2017
Jun 30, 2017
$0
Aug 8, 2017
Q1
2017
Mar 31, 2017
$0
May 15, 2017
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
$2.21M
Mar 9, 2026
Q2
2026
Sep 30, 2025
($869.5K)
Nov 26, 2025
Q3
2026
Sep 30, 2025
($869.5K)
Mar 9, 2026
Q2
2026
Jun 30, 2025
($5.06M)
Nov 26, 2025
Q3
2026
Jun 30, 2025
($5.06M)
Mar 9, 2026
Q1
2025
Mar 31, 2025
($1.44M)
May 13, 2025
Q3
2026
Dec 31, 2024
($850.3K)
Mar 9, 2026
Q2
2026
Sep 30, 2024
($582.4K)
Nov 26, 2025
Q3
2026
Sep 30, 2024
($582.4K)
Mar 9, 2026
Q2
2026
Jun 30, 2024
($324.4K)
Nov 26, 2025
Q3
2026
Jun 30, 2024
($324.4K)
Mar 9, 2026
Q1
2025
Mar 31, 2024
($1.72M)
May 13, 2025
Q3
2024
Mar 31, 2024
($1.72M)
Nov 14, 2024
Q2
2024
Mar 31, 2024
($1.72M)
Aug 14, 2024
Q3
2024
Sep 30, 2023
($1.40M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.21M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($1.21M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($718.1K)
May 15, 2024
Q3
2024
Mar 31, 2023
($718.1K)
Nov 14, 2024
Q2
2024
Mar 31, 2023
($718.1K)
Aug 14, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
($925.1K)
Mar 9, 2026
Q2
2026
Sep 30, 2025
($1.11M)
Nov 26, 2025
Q1
2025
Mar 31, 2025
($1.45M)
May 13, 2025
Q3
2026
Dec 31, 2024
($401.4K)
Mar 9, 2026
Q2
2026
Sep 30, 2024
($355.4K)
Nov 26, 2025
Q3
2024
Sep 30, 2024
($652.1K)
Nov 14, 2024
Q2
2024
Jun 30, 2024
($1.67M)
Aug 14, 2024
Q1
2025
Mar 31, 2024
($1.74M)
May 13, 2025
Q3
2024
Sep 30, 2023
($1.43M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.14M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($739.3K)
May 15, 2024
Q3
2023
Sep 30, 2022
($924.1K)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($636.7K)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($1.34M)
May 15, 2023
Q3
2022
Sep 30, 2021
($764.2K)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($1.31M)
Aug 11, 2022
Q1
2022
Mar 31, 2021
($1.21M)
May 13, 2022
Q3
2021
Sep 30, 2020
($1.09M)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($488.9K)
Aug 16, 2021
Q1
2021
Mar 31, 2020
($520.7K)
May 17, 2021